In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge by Moon, A.M. et al.
RESEARCH ARTICLE
In inpatients with cirrhosis opioid use is
common and associated with length of stay
and persistent use post-discharge
Andrew M. MoonID
1*, Yue Jiang2, Shari S. Rogal3, Jasper Becker4, A. Sidney Barritt IV1
1 Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC,
United States of America, 2 Department of Statistical Science, Duke University, Durham, NC, United States
of America, 3 Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh,
PA, United States of America, 4 North Carolina Translational and Clinical Sciences Institute (NC TraCS),




Previous studies have demonstrated that opioids are often prescribed and associated with
complications in outpatients with cirrhosis. Less is known about opioids among hospitalized
patients with cirrhosis. We aimed to describe the patterns and complications of opioid use
among inpatients with cirrhosis.
Methods
This retrospective cohort study included adult patients with cirrhosis admitted to a single
hospital system from 4/4/2014 to 9/30/2015. We excluded hospitalizations with a surgery,
invasive procedure, or palliative care/hospice consult in order to understand opioid use that
may be avoidable. We determined the frequency, dosage, and type of opioids given during
hospitalization. Using bivariable and multivariable analyses, we assessed length of stay,
intensive care unit transfer, and in-hospital mortality by opioid use.
Results
Of 217 inpatients with cirrhosis, 118 (54.4%) received opioids during hospitalization, includ-
ing 41.7% of patients without prior outpatient opioid prescriptions. Benzodiazepines or hyp-
notic sleep aids were given to 28.8% of opioid recipients. In the multivariable model,
younger age and outpatient opioid prescription were associated with inpatient opioids. Hos-
pitalization was longer among opioid recipients (median 3.9 vs 3.0 days, p = 0.002) and this
difference remained after adjusting for age, cirrhosis severity, and medical comorbidities.
There was no difference in intensive care unit transfers and no deaths occurred. At dis-
charge, 22 patients were newly started on opioids of whom 10 (45.5%) had opioid prescrip-
tions at 90 days post-discharge.
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Conclusion
In non-surgical inpatients with cirrhosis, opioid prescribing was common and associated
with prolonged length of stay. A high proportion of patients newly discharged with opioid pre-
scriptions had ongoing prescriptions at 90 days post-discharge.
Introduction
Pain is common among patients with cirrhosis and analgesia for these patients can be difficult
[1–3]. Given the presumed limitations of using high-dose acetaminophen and nonsteroidal
anti-inflammatory drugs (NSAIDs), short-acting opioids are commonly used in patients with
cirrhosis [2, 4]. The prevalence and potential complications of opioid use among those with
cirrhosis remain unclear, particularly for hospitalized patients.
Previous studies have examined opioid prescriptions among patients with cirrhosis in the
outpatient and hospital discharge settings [1, 4–6]. These studies identified patient characteris-
tics associated with opioid prescription including sleep disturbance, psychiatric comorbidities,
and past substance use. In these populations opioids were associated with increased overall
health care utilization and hospital readmissions [5, 6].
The patterns of opioid prescribing among hospitalized patients with cirrhosis are relatively
understudied. Opioids likely increase the risk of complications in patients with cirrhosis [5, 7,
8], especially when used in combination with benzodiazepines [9, 10]. Furthermore, inpatient
opioids may lead to chronic use in some patients. Of all opioid naïve patients admitted to the
hospital, 15–25% receive a new prescription for opioids, 43% of whom subsequently fill an opi-
oid prescription 90 days post-discharge [11, 12]. This is concerning given opioids’ demon-
strated harms and lacking efficacy data for chronic pain [13–16].
We therefore aimed to describe patterns of inpatient opioid prescribing among patients
with cirrhosis at a single tertiary medical center and assess patient characteristics associated
with inpatient opioid prescribing. We additionally evaluated the association between opioid
prescriptions and length of stay, transfer to the intensive care unit (ICU), inpatient mortality,
and 30-day readmission. Lastly, we assessed the prevalence and indications for opioid pre-
scriptions at discharge and, for new opioid starts, determined whether patients remained on
opioids at 30 days and 90 days post-discharge.
Materials and methods
Study design
This was a retrospective cohort study within the University of North Carolina (UNC) hospital
system. All data were obtained by extraction through the Carolina Data Warehouse for Health
(CDW-H) and subsequent review of the electronic medical record. The CDW-H is a central
data repository containing administrative, research, and clinical data from the UNC Health
Care System from mid-2004 to present. This project was approved by the UNC Institutional
Review Board (IRB).
Patient selection
We included all patients�18 years old admitted to UNC hospitals from April 4, 2014 to Sep-
tember 30, 2015 with�2 pre-admission International Classification of Diseases, 9th revision,
clinical modification (ICD-9-CM) codes for cirrhosis or its complications (Table 1). This defi-
nition has been used and validated in previous publications [17–19]. The diagnosis of cirrhosis
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was verified in all patients by individual chart review. We excluded patients with prior liver
transplant unless they developed recurrent cirrhosis. The start date of April 4, 2014 was chosen
because this is when UNC hospitals began use of the Epic electronic medical record, which
allowed complete capture of inpatient opioid use. The end date of September 30, 2015 was
when ICD-9 was replaced with ICD-10 coding, which lacks the rigorous validation for defini-
tions of cirrhosis and patient comorbidities.
By chart review, we identified and excluded admissions with a recent (within 7 days of
admission or during hospitalization) surgery or invasive procedure (e.g. chest tube, transcath-
eter arterial chemoembolization, transjugular intrahepatic portosystemic shunt). Minimally
invasive procedures such as paracentesis and upper endoscopy were not considered invasive
procedures in this definition. We also excluded hospitalizations in which a palliative care con-
sult for pain management or comfort care/hospice referral occurred, given that the balance of
opioids’ benefits and risks may be different for this population. We only considered a patient’s
first admission.
Patient characteristics
We extracted primary admission diagnosis and patient demographics including sex, race, and
age. We calculated body mass index (BMI) at the time of admission as weight in kilograms
divided by height in meters squared. We determined each patient’s admission team and
Table 1. ICD-9-CM coding definitions.
ICD-9 codes used










Charlson Comorbidity Score 410–410.9 (myocardial infarction, Charlson score 1);
428–428.9 (congestive heart failure, Charlson score 1);
433.9, 441–441.9, 785.4, V43.4 (peripheral vascular disease, Charlson score 1);
430–438 (Cerebrovascular Disease, Charlson score 1);
290–290.9 (Dementia, Charlson score 1);
490–496, 500–505, 506.4 (Chronic Pulmonary Disease, Charlson score 1);
710.0, 710.1, 710.4, 714.0–714.2, 714.81, 725 (Rheumatologic Disease, Charlson
score 1);
531–534.9 (Peptic Ulcer Disease, Charlson score 1);
571.2, 571.5, 571.6, 571.4–571.49 (Mild Liver Disease, Charlson score 1);
250–250.3, 250.7 (Diabetes, Charlson score 1);
250.4–250.6 (Diabetes with Chronic Complications, Charlson score 2);
344.1, 342–342.9 (Hemiplegia or Paraplegia, Charlson score 2);
582–582.9, 583–583.7, 585, 586, 588–588.9 (Renal Disease, Charlson score 2);
572.2–572.8 (Moderate or Severe Liver Disease, Charlson score 3);
042–044.9 (AIDS, Charlson score 6)
ESRD/hemodialysis V45.1, V56.0, V56.1, CPT 39.95
Depression 296.20–25, 296.30–35, 300.4, 311
Anxiety 300.00–300.02
Substance abuse/dependence 305.00–305.95, 304.40–304.93
ICD-9-CM: International Classification of Diseases, 9th revision, clinical modification; AIDS: acquired immune
deficiency syndrome; ESRD: end stage renal disease; CPT: Current Procedural Terminology
https://doi.org/10.1371/journal.pone.0229497.t001
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limited our analysis to patients admitted to the internal medicine or family medicine inpatient
services. This was done to minimize the inclusion of patients with painful surgical issues who
did not receive surgery due to cirrhosis or other medical comorbidities. We identified outpa-
tient prescriptions for opioids at the time of admission by individual chart review. We deter-
mined substance abuse/dependence, depression and anxiety based on the presence of ICD-9
codes before the date of admission. We calculated the Charlson Comorbidity Index (CCI) for
each patient [20].
We determined etiology of liver disease by individual review of labs, imaging and clinical
notes and categorized etiologies as hepatitis C virus (HCV), alcohol-associated, HCV/alcohol,
non-alcoholic fatty liver disease (NAFLD), hepatitis B virus (HBV), and other. We assessed
severity of liver disease via the Model for End Stage Liver Disease (MELD) score, MELD-Na
score, and the presence of pre-admission decompensation events [21]. We extracted admission
laboratory values and performed chart review to determine if patients were on hemodialysis
within the prior week. For cirrhosis complications, we required at least two preadmission
ICD-9 codes for esophageal varices, spontaneous bacterial peritonitis, hepatic encephalopathy,
hepatorenal syndrome, or hepatocellular carcinoma (HCC) (Table 1). These definitions of cir-
rhosis complications have been previously validated and used [18, 22, 23].
Assessment of opioid use and associated complications
Among patients who received opioids, we extracted data from the CDW-H to determine
cumulative opioid doses from the time of first contact in the emergency department until ICU
transfer, discharge, or death. We calculated the morphine milligram equivalent (MME) using
standard tables [13, 24]. We excluded all opioids given for sedation (e.g., intravenous fentanyl)
and patients who exclusively received intravenous fentanyl were considered to not have
received opioids. We determined the indication for inpatient opioid prescriptions by review-
ing the electronic medical record. We assessed whether patients were discharged with pre-
scriptions for opioid medications and reviewed charts to assess the reasons for opioid
prescriptions at discharge. For new opioid starts, we assessed if patients had a subsequent opi-
oid prescription within a month of discharge and/or an active prescription at 90 days post-dis-
charge. We also determined reasons for opioid discontinuations among patients with pre-
admission opioid prescriptions.
We ascertained the in-hospital use of non-opioid analgesics including NSAIDs, acetamino-
phen, gabapentinoids (gabapentin/pregabalin), tricyclic antidepressants (TCAs), serotonin and
norepinephrine reuptake inhibitors (SNRIs), muscle relaxants, and topical analgesics. Lastly, we
determined if patients received benzodiazepines or hypnotic sleep aids during hospitalization.
We determined the total length of stay, ICU transfer, in-hospital mortality, and 30-day
readmission using the CDW-H and confirmed these outcomes via individual chart review.
Statistical analysis
Statistical analyses were carried out using R version 3.4.2 (Vienna, Austria).[25] We calculated
patients’ total MME during hospitalization and determined median and interquartile range
(IQR) for daily MME among opioid recipients. We determined the number of days of opioid
use by counting the number of unique hospital days patients received opioids. We classified
opioid use as a dichotomous variable (any/none) and presented patients’ daily opioid use (by
MME) in a histogram, stratified by outpatient opioid prescription. We performed bivariable
analyses to assess patient characteristics associated with inpatient receipt of opioids, using t-
tests, χ2 tests, and Fisher’s exact tests where appropriate. To evaluate variables associated with
inpatient prescription of opioids, a multivariable logistic regression model was created and
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included patient demographics, MELD, CCI, depression, and pre-admission outpatient opioid
prescription. We used logistic regression to assess variables associated with ICU transfer and
in-hospital mortality, including inpatient opioids, age, MELD, and CCI. Lastly, multivariable
Poisson regression with robust standard errors was performed to assess variables associated
with length of stay. For multivariable models, we included covariates that were deemed to be
potential confounders in the relationship between opioid use and relevant outcomes. These
variables were chosen a priori. P-values <0.05 (two-sided) were considered statistically signifi-
cant in all analyses.
Results
Overall patient and hospitalization characteristics
After excluding patients with recent surgeries/invasive procedures or palliative care/hospice
referrals, we identified 217 inpatients with cirrhosis (Fig 1). Patients had a median age of 59.4
years (IQR 53.5–65.4) and were predominantly male (65.9%) and white (79.7%) (Table 2).
Most patients had cirrhosis from alcohol (30.9%) and the median admission MELD-Na score
was 16.7 (IQR 14.3–22.1). Most primary admission diagnoses were liver-related (n = 74,
34.1%) or for digestive disorders (n = 64, 29.5%). Median length of stay was 3.6 days (IQR 2.4–
5.7), there were 11 (5.1%) ICU transfers, and no in-hospital deaths occurred (Table 3).
Characteristics of inpatient opioid recipients vs non-recipients
During hospitalization, 118 patients with cirrhosis (54.4%) received opioids (Table 1). In addi-
tion, 10 patients received opioids for procedural sedation exclusively and were therefore not
considered to have received inpatient opioids. In bivariable analyses, inpatient opioid adminis-
tration was associated with outpatient opioid prescriptions (72.2% vs 27.8%, p<0.001), youn-
ger age (58.0 vs 62.6 years, p = 0.002), and depression (67.1% vs. 32.9%, p = 0.003). The
admission diagnoses for patients receiving opioids were less likely to be infectious (4.2% vs
15.2%, p = 0.008) or mental health/substance-related (1.7% vs 12.1%, p = 0.002). Among opi-
oid recipients, 16 (13.6%) had a primary admission diagnosis of hepatic encephalopathy.
In our multivariable logistic regression model (Table 4), younger age (OR 0.96, 95% CI
0.93–0.99) and outpatient opioid prescription (OR 3.96, 95% CI 2.13–7.56) were significantly
associated with increased odds of receiving opioids during hospitalization.
Characteristics of opioid and non-opioid analgesic use
Among all patients who received inpatient opioids (n = 118), the median daily MME was 9.8
mg (IQR 3.2–23.0) (Table 5). Opioid recipients were prescribed at least one dose for a median
of 3 hospital days and 36 (30.5%) patients received opioids over�1 hospital day. The majority
of patients received� 50 MME/day, although daily doses of 50–100 MME were more common
among patients with prior outpatient opioid prescriptions (Fig 2). Of opioid recipients, the
most commonly prescribed opioid was oxycodone (62.7%) and 65 (55.1%) patients received
multiple opioids. Benzodiazepines or hypnotic sleep aids were given to 62 (28.6%) of 276
patients overall, with no statistically significant difference between opioid recipients (28.8%)
and non-recipients (28.3%) (p>0.999). The most common indication for inpatient opioids
was GI-related pain (36.4%) followed by musculoskeletal (MSK) indications (33.9%) (Table 6).
There was no indication for opioids mentioned within any notes for 21 (17.8%) patients.
At discharge, 101 patients received an outpatient prescription for opioids, 22 of which were
new opioid prescriptions. Of the 22 patients with new opioid prescriptions, 19 (86.4%) had a
potentially painful condition mentioned in the discharge summary including infections
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(cellulitis), trauma, and malignancy (HCC) (Table 7). However, others were prescribed opioids
despite relative contraindications to their use (e.g. abdominal pain from ileus, C difficile coli-
tis). Explicit documentation of the indication for opioids was provided in only 8 of 22 (36.4%)
discharge summaries. The median daily MME of these opioid prescriptions was 37.5 (IQR
20.0–45.0) mg/day. Post-discharge, 14 (63.6%) of 22 patients with new opioid prescriptions at
discharge received an additional opioid prescription within 30 days and 10 (45.5%) had an opi-
oid prescription at 90 days post-discharge.
Fig 1. Flow diagram of inpatient cohort. Flow diagram demonstrating the number of patients with cirrhosis admitted to the University of North
Carolina (UNC) hospitals during the study period and the numbers included in the analysis after excluding recent surgeries or invasive procedures
or hospice/palliative care/comfort care consultations. Among those included in the final cohort, the proportion receiving opioids stratified by
outpatient opioid prescription is shown. Lastly, the number of patients discharged on opioids is demonstrated.
https://doi.org/10.1371/journal.pone.0229497.g001
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There were 11 patients with pre-hospitalization opioid prescriptions who were not dis-
charged on opioids. The reason for discontinuing opioids was hepatic encephalopathy for 6
patients, polysubstance abuse in two, and altered mental status of unclear etiology in one. For
two patients, there was no clear reason for stopping opioid prescriptions listed.
During hospitalization, a minority of patients received non-opioid analgesics (Table 3).
Among those who received opioids, there was a significantly higher proportion who also
received gabapentanoids (17.8% vs 7.1%, p = 0.024) and topical analgesics (11.0% vs 3.0%,
p = 0.035). Only 27.1% of opioid recipients received acetaminophen.
Potential complications of opioid use
Length of hospitalization was significantly longer among patients who received inpatient opi-
oids (median 3.9, IQR 2.7–5.8 days) compared to those who did not receive opioids (median
3.0, IQR 2.0–4.7 days) (p = 0.002) (Table 3). There were similar numbers of ICU transfers
among those who received opioids (4.2%) and those who did not receive opioids (6.1%)






Age (years) 58.0 (52.8–64.2) 62.6 (54.0–67.6) 0.002
Sex Female 43 (58.1%) 31 (41.9%) 0.474
Male 75 (52.4%) 68 (47.6%)
Race White 96 (55.5%) 77 (44.5%) 0.394
Black 16 (57.1%) 12 (42.9%)
Other 6 (37.5%) 10 (62.5%)
Body Mass Index (at admission) 28.4 (24.0–34.8) 28.1 (24.4–32.5) 0.709
Etiology of Cirrhosis HCV 19 (63.3%) 11 (36.7%) 0.098
Alcohol 30 (44.8%) 37 (55.2%)
HCV/Alcohol 23 (67.6%) 11 (32.4%)
NAFLD 21 (50.0%) 21 (50.0%)
HBV 1 (20.0%) 4 (80.0%)
Other 24 (61.5%) 15 (38.5%)
MELD score (at admission) 13.9 (10.7–18.5) 15.0 (12.3–20.2) 0.101
MELD-Na score (at admission) 16.4 (10.7–21.4) 17.8 (14.9–22.3) 0.065
Cirrhosis Complications (pre-admission) Hepatic encephalopathy 42 (51.2%) 40 (48.8%) 0.574
Ascites 80 (54.1%) 68 (45.9%) >0.999
HCC 9 (52.9%) 8 (47.1%) >0.999
Hepatorenal syndrome 2 (28.6%) 5 (71.4%) 0.251
Spontaneous bacterial peritonitis 10 (50.0%) 10 (50.0%) 0.815
Esophageal varices with bleeding 80 (56.7%) 61 (43.3%) 0.318
ESRD/hemodialysis 2 (40.0%) 3 (60.0%) 0.662
Charlson Comorbidity Score 8.0 (6.0–11.0) 8.0 (6.0–11.0) 0.930
Depression 57 (67.1%) 28 (32.9%) 0.003
Anxiety 31 (58.5%) 22 (41.5%) 0.527
Substance Abuse/Dependence 1 (100.0%) 0 (0.0%) >0.999
Outpatient Opioid Prescription 65 (72.2%) 25 (27.8%) <0.001
Medians (IQRs) listed for all categorical variables; All statistically significant associations are in bold; HCV: hepatitis C virus; NAFLD: non-alcoholic fatty liver disease;
HBV: hepatitis B virus; MELD: Model for End-Stage Liver Disease; HCC: hepatocellular carcinoma; ESRD: end-stage renal disease
https://doi.org/10.1371/journal.pone.0229497.t002
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(p = 0.554). There were no in-hospital deaths in either group. Overall, 24.0% of patients had
readmissions within 30 days with no significant differences between opioid recipients (26.3%)
and non-recipients (21.2%) (p = 0.290).
Both inpatient opioid use (estimate 0.418, 95% CI 0.202–0.633) and higher MELD (estimate
0.034, 95% CI 0.012–0.055) were associated with length of stay in the adjusted Poisson regres-
sion model (Table 8). In the logistic regression model, only MELD (OR 1.13, 95% CI 1.03–
1.25) was independently associated with ICU transfer (Table 9).










Admission Team Family Medicine 31 (14.3%) 16 (14.9%) 15 (15.2%) 0.803
Internal Medicine (teaching) 156 (71.9%) 87 (81.1%) 69 (69.7%)
Internal Medicine (non-
teaching)
30 (13.8%) 15 (14.0%) 15 (15.2%)
Non-opioid analgesics during
hospitalization
NSAID 5 (2.3%) 2 (1.7%) 3 (3.0%) 0.662
Acetaminophen 56 (25.8%) 32 (27.1%) 24 (24.2%) 0.644
Gabapentinoid 28 (12.9%) 21 (17.8%) 7 (7.1%) 0.024
TCA 4 (1.8%) 4 (3.4%) 0 (0.0%) 0.127
SNRI 2 (0.9%) 2 (1.7%) 0 (0.0%) 0.502
Muscle relaxant 5 (2.3%) 4 (3.4%) 1 (1.0%) 0.379
Topical analgesic 16 (7.4%) 13 (11.0%) 3 (3.0%) 0.035
Benzodiazepine or hypnotic sleep aid during hospitalization 62 (28.6%) 34 (28.8%) 28 (28.3%) >0.999








ICU transfer 11 (5.1%) 5 (4.2%) 6 (6.1%) 0.554
In-hospital mortality 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.999
30-day readmission 52 (24.0%) 31 (26.3%) 21 (21.2%) 0.290
All statistically significant associations are in bold; NSAID: nonsteroidal anti-inflammatory drug; TCA: tricyclic antidepressant; SNRI: serotonin and norepinephrine
reuptake inhibitor; ICU: intensive care unit
https://doi.org/10.1371/journal.pone.0229497.t003
Table 4. Adjusted multivariable analysis of opioid use.
Characteristic OR (95% CI)
Age (years) 0.96 (0.93, 0.99)
Gender (Female = referent)
Male 0.67 (0.35, 1.26)
Race (Black = referent)
White 0.79 (0.31, 1.96)
Other 0.25 (0.06, 1.00)
Outpatient Opioid Prescription 3.96 (2.13, 7.56)
MELD score at admission 0.97 (0.91, 1.02)
Depression 1.89 (1.00, 3.61)
CCI 0.97 (0.89, 1.06)
Logistic regression used to calculate CI and p-values for opioid use during hospitalization; significant associations in
bold; MELD: Model for End-Stage Liver Disease; CCI: Charlson Comorbidity Index
https://doi.org/10.1371/journal.pone.0229497.t004
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Discussion
In this single-center, retrospective cohort study, we found that inpatient opioid use was com-
mon among non-surgical patients with cirrhosis and associated with prolonged length of stay.
Over half (54.4%) of patients received opioids during hospitalization, including 41.7% of all
patients without pre-hospitalization opioid prescriptions. A significant proportion of opioid
recipients (28.8%) also received benzodiazepines or hypnotic sleep aids during hospitalization.
Those who received opioids were hospitalized for nearly a day longer. A total of 22 of 127
(17.3%) patients who were previously opioid-naïve received new opioid prescriptions at the
time of discharge and 10 of these patients had an opioid prescription at 90 days post-
discharge.
The prevalence of inpatient opioid use in our cirrhotic population was slightly higher than
has been previously reported in both non-cirrhotic and cirrhotic populations. A large retro-
spective cohort study reported that half of non-surgical patients hospitalized in the US receive
at least 1 dose of opioids [26] and a single-center, prospective cohort study reported that 41.5%
of patients with cirrhosis received opioids during hospitalization [6].
We identified a statistically significant association between opioid use and prolonged
length-of-stay, even after adjusting for age, MELD, and CCI. There are several potential rea-
sons that may explain this association. Given their known side effects and decreased clearance
in cirrhosis, opioids may contribute to adverse events during hospitalization including falls,
delirium, hepatic encephalopathy, and opioid overdose [3, 7]. In our cohort, there was evi-
dence of high-risk prescribing, including opioid receipt among patients with a primary diag-
nosis of hepatic encephalopathy and receipt of opioids in combination with benzodiazepines,
which is explicitly discouraged in current guideline [13].
In addition to increasing risk of adverse events and prolonged length of stay, inpatient opi-
oid use can lead to chronic opioid use and dependence [11, 12]. Among patients in our cohort
newly discharged on opioids, 63.2% received an additional opioid prescription within 30 days
Table 5. Characteristics of opioid use during hospitalization.
Opioid Recipients (n = 118)
Median MME (mg/day),
For patients with inpatient opioid prescriptions
9.8 (IQR 3.2–23.0)











Opioid prescription at discharge 101 (85.6%)
New opioid prescription at discharge 22 (18.6%)
Average morphine equivalent calculated by summing each inpatient opioid administration aggregated by patient
divided by individual hospitalization length in days
� Fentanyl count only includes transdermal patch and PCA
https://doi.org/10.1371/journal.pone.0229497.t005
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of hospitalization and 45.5% had an opioid prescription 90 days post-discharge. This demon-
strates the considerable risk of chronic opioid use among patients newly discharged on opioid
therapy after hospitalization. Opioid use in patients with cirrhosis has also been associated
with an increased risk of hepatic encephalopathy [27, 28], health care utilization [5], hospital
readmissions [6], respiratory depression or overdose [29], and decreased health-related quality
of life [30].
Patients with cirrhosis often require short-term analgesia during hospitalization but the
lack of painful comorbidities noted in documentation suggests that opioid use could have been
minimized [1, 6]. Adjunctive non-opioid analgesics were used infrequently in this cohort.
Acetaminophen, which can be safely used at moderate doses (<2 g/day) in cirrhotic patients,
Fig 2. Histogram of average daily opioid use stratified by outpatient prescription of opioids. Histogram demonstrating the
frequency of patients by the average morphine milligram equivalent (MME) per day among patients with and without an outpatient
opioid prescription. The numerator is the total summed dose, converted into morphine equivalents, divided by the total length of
hospitalization; patients on patient controlled analgesia were considered in the highest quartile.
https://doi.org/10.1371/journal.pone.0229497.g002
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was only given to a quarter of patients who received inpatient opioids [3]. While topical anal-
gesics were more frequently prescribed among those who received opioids, the proportion of
opioid recipients who received them was low. Gabapentin/pregabalin was used relatively infre-
quently but more often in opioid recipients. Combined use of gabapentin and opioids might
increase the risk of adverse events since both medications can cause somnolence [3, 31].
Although our study provides novel insights on the prevalence, patterns, and complications
of inpatient opioid use, it has some potential limitations. First, our population had a lower
than expected number of ICU transfers (n = 11) and in-patient deaths (n = 0), precluding
assessment of the potential effect of inpatient opioids on these important outcomes. However,
Table 6. Indications for opioid use during hospitalization.
Category Cause Count












Gastric outlet obstruction 1
Musculoskeletal (n = 40) Chronic back pain 15
Chronic joint pain 10
Cellulitis 5
Chronic ulcer 2
Acute trauma without fracture 2
Bone fracture 1
Lytic bone lesions 1
Pleurisy 1
Pyoderma gangrenosum 1
Leg pain from peripheral vascular disease 1
Chest pain (presumed MSK) 1
Other (n = 12) Headache 3
Venous thrombosis 1




Previously placed peritoneal catheter 1
Generalized pain 1
Allodynia (unclear etiology) 1
Multiple causes listed (n = 2) Abdominal and back pain 1
Abdominal and leg pain 1
No indication listed (n = 21) - -
GI: gastrointestinal; SBP: spontaneous bacterial peritonitis; HCC: hepatocellular carcinoma; MSK: musculoskeletal
https://doi.org/10.1371/journal.pone.0229497.t006
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we were able to assess the associations between opioids and length of stay and post-hospitaliza-
tion opioid prescriptions. There is a potential for residual confounding by indication in our
multivariable analysis of length of stay, but we attempted to reduce this risk by excluding ICU
admissions/surgeries and adjusting for cirrhosis severity and comorbidities. In addition, we
assessed the reason for admission and indication for opioid prescription by performing chart
review. Moreover, given our exclusion criteria, our findings should not be used to guide
Table 7. Outpatient opioid prescriptions among previously opioid-naïve patients.
Characteristic All Patients (n = 22)
Median MME (mg/day) 37.5 (IQR 20.0–45.0)
Reason for opioid documented 8 (36.4%)
Possible indication (n = 19) SBP (n = 3)
Cellulitis (n = 3)
Minor trauma (n = 2)
Endoscopic intervention (n = 2)
HCC (n = 1)
Pyoderma gangrenosum (n = 1)
Degenerative disk disease (n = 1)
Pancreatitis (n = 1)
Periumbilical hernia (n = 1)
Abdominal pain from ileus (n = 1)
C. difficile colitis (n = 1)
Hypertensive headaches (n = 1)
Chest tube replacement (n = 1)
Pleurisy (n = 1)
Additional opioid prescription within 1 month 14 (63.6%)
Active opioid prescription 90 days post-discharge 10 (45.5%)
MME: morphine milligram equivalent; SBP: spontaneous bacterial peritonitis; HCC: hepatocellular carcinoma; MSK:
musculoskeletal
https://doi.org/10.1371/journal.pone.0229497.t007
Table 8. Adjusted multivariable analysis of length of stay.
Length of Stay (days) Estimate (95% CI)
Inpatient opioid use 0.418 (0.202, 0.633)
Age (years) 0.000 (-0.012, 0.011)
MELD 0.034 (0.012, 0.055)
CCI 0.026 (-0.003, 0.055)
� Poisson regression with robust standard errors used to calculate CI and p-values for length of stay; significant
associations in bold; MELD: Model for End-Stage Liver Disease; CCI: Charlson Comorbidity Index
https://doi.org/10.1371/journal.pone.0229497.t008
Table 9. Adjusted multivariable analysis of ICU transfers.
ICU Transfer OR (95% CI)
Inpatient opioid use 0.81 (0.22, 2.95)
Age (years) 1.01 (0.95, 1.07)
MELD 1.13 (1.03, 1.25)
CCI 0.99 (0.83, 1.18)
� Logistic regression used to calculate CI and p-values for ICU transfers during hospitalization; significant
associations in bold; MELD: Model for End-Stage Liver Disease; CCI: Charlson Comorbidity Index
https://doi.org/10.1371/journal.pone.0229497.t009
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decisions for post-surgical patients or patients referred for palliative analgesia. However, the
exclusion of these patients allowed a unique investigation of inpatients with cirrhosis admitted
primarily for medical reasons. It is critical to interpret these results in the context of shifting
opioid-related policies. For example, in 2016, the Centers for Disease Control and Prevention
changed their guidelines around opioid prescribing. Additionally North Carolina’s STOP Act,
which was enacted in 2017, was aimed at curbing unsafe opioid prescribing. Given these
changes in policy and the national attention on opioid safety, it is possible that opioid prescrib-
ing practices have evolved since data collection. Future research should assess time-trends in
opioid prescribing [13].
In conclusion, in this study of non-surgical inpatients with cirrhosis, opioid use was com-
mon and associated with increased length of stay. Over one-fourth of opioid recipients were
also given benzodiazepines or hypnotic sleep aids. A high proportion of previously opioid
naïve patients were discharged on opioids and received opioid prescriptions at 90 days post-
discharge. These findings provide important information on the patterns of inpatient opioid
use among patients with cirrhosis and identify high-risk prescribing practices that could be
addressed with quality improvement efforts.
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